MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals (” MyMD” or “the Company”), a clinical phase pharmaceutical business dedicated to prolonging healthy life-span, today revealed that the initial individual has been enrolled in the Company’s Phase 2 scientific test of lead prospect MYMD-1, an oral immune regulatory authority medication, as a therapy for delaying aging and broadening healthy and balanced life-span.
The primary endpoint for the Phase 2 double-blind, placebo-controlled medical trial is to accomplish a decrease in the circulating levels of (TNF-α), tumor death aspect receptor I (TNFRI) as well as IL-6. TNF-α as well as IL-6 are the proteins in the body that create swelling and also assist turn on the process of aging. The second actions of the test will be the safety and security, tolerability, as well as pharmacokinetics in this population of people.
” In a Phase 1 professional test of MYMD-1, we showed the drug’s statistically substantial effectiveness in lowering degrees of TNF-α, a key player in causing pathological aging, in the blood. The FDA has actually authorized TNF-α decrease as the primary endpoint for our Phase 2 research, which we believe placements us well for an effective Phase 2 end result,” said Chris Chapman, M.D., President, Director as well as Chief Medical Policeman of MyMD. “The initiation of patient registration in this study advancements our objective to slow the aging process, avoid loss of muscle mass cells in aging, limit frailty, as well as prolong healthy and balanced life expectancy.”
MyMD has actually mentioned that there are no FDA-approved medicines for treating aging conditions and extending healthy life-span human beings, a market anticipated to be at least $600 billion by 20251 according to a major financial investment bank. TNF-α blockers are the most recommended drugs by revenue, a global market of approximately $40 billion per year,2 as well as, according to Nature Aging journal,3 a downturn in aging that would certainly enhance life span by one year deserves $38 trillion and by ten years is worth $367 trillion.
In addition to aging, MYMD-1’s distinct activity in regulating the immune system and also dealing with chronic inflammation is being established for the therapy of autoimmune condition, including rheumatoid arthritis (RA), multiple sclerosis (MS), diabetes, and also inflammatory digestive tract disease.
” We intend to begin writing methods for a Stage 2 pilot research of MYMD-1 for rheumatoid arthritis early this year,” Dr. Chapman noted. “The increasing prevalence of rheumatoid joint inflammation and also various other autoimmune and also inflammatory conditions are driving demand for TNF preventions like MYMD-1, and our team believe our by mouth administered drug with very reduced toxicity would be turbulent to the $60 billion market for RA if accepted by the FDA for this indicator.”
Rheumatoid arthritis influences around 40 million individuals worldwide.4.
Originally created for autoimmune conditions, MYMD-1’s primary function is to reduce the aging process, avoid sarcopenia and also frailty, and also extend healthy life-span. Since it can go across the blood-brain obstacle and get to the central nervous system (CNS), MYMD-1 is likewise positioned to be a possible treatment for brain-related conditions. Its device of activity and also efficacy in diseases consisting of multiple sclerosis (MS) and also thyroiditis have been studied via cooperations with numerous academic organizations. MYMD-1 is additionally revealing pledge in pre-clinical studies as a prospective treatment for blog post- COVID-19 problems and as an anti-fibrotic as well as anti-proliferation restorative.
MYMD-1 has revealed effectiveness in pre-clinical research studies in managing the immune system by doing as a selective prevention of lump necrosis factor-alpha (TNF-α), a driver of chronic swelling. Unlike other therapies, MYMD-1 has actually been shown in these pre-clinical researches to precisely block TNF-α when it ends up being overactivated in autoimmune diseases and cytokine storms, but not block it from doing its normal work of being a first -responder to any routine kind of modest infection. MYMD-1’s convenience of oral dosing is another differentiator contrasted to currently readily available TNF-α blockers, all of which need delivery by injection or mixture. No approved TNF inhibitor has actually ever before been dosed orally. In addition, the medicine is not immunosuppressive and also has actually not been shown to trigger the major adverse effects typical with conventional therapies that treat inflammation.
About MyMD Pharmaceuticals, Inc
. MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a clinical phase pharmaceutical firm devoted to expanding healthy and balanced life expectancy, is concentrated on developing two unique therapeutic platforms that treat the sources of condition instead of just attending to the symptoms. MYMD-1 is a drug platform based upon a clinical phase little particle that manages the body immune system to control TNF-α, which drives persistent inflammation, as well as other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to postpone aging, rise long life, as well as treat autoimmune illness as well as COVID-19- linked depression. The Firm’s 2nd drug system, Supera-CBD, is being established to treat persistent pain, addiction as well as epilepsy. Supera-CBD is an unique synthetic by-product of cannabidiol (CBD) and is being developed to attend to and surpass the swiftly growing CBD market, that includes both FDA approved medicines and CBD products not presently controlled as medicines. For more information, go to www.mymd.com.